# Endo Prefer Nsaid Dmard

> Recommends using NSAIDs or DMARDs instead of glucocorticoids for chronic inflammatory disease (e.g., rheumatoid arthritis) to limit weight gain. Triggered when clinicians ask, “What anti‑inflammatory should I choose for this RA patient to avoid weight gain?” or “Should I avoid steroids in this obese patient with RA?”

- Skill: `dromlakhani/endo-prefer-nsaid-dmard` (Agent Skill)
- Install (CLI): `npx skillmds add dromlakhani/endo-prefer-nsaid-dmard`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-prefer-nsaid-dmard/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-08-19
- Page: https://skillmd.com/skills/dromlakhani/endo-prefer-nsaid-dmard

---


# Prefer NSAIDs/DMARDs over corticosteroids in chronic inflammatory disease to avoid weight gain

## STEP 1 — Gather Information
Collect diagnosis of chronic inflammatory disease (e.g., RA), disease activity score, comorbidities (obesity, diabetes, hypertension, CKD, GI disease), current medications, contraindications to NSAIDs/DMARDs (active ulcer, CKD stage 4‑5, heart failure, immunosuppression need), baseline weight/BMI, and patient preferences.  
**Action:** Proceed to assess suitability for NSAID/DMARD therapy.

## STEP 2 — Rule In / Rule Out
Is there a contraindication to NSAIDs or DMARDs (e.g., active peptic ulcer, eGFR < 30 mL/min, NYHA III‑IV heart failure, need for ongoing immunosuppression)?  
- **Yes:** Rule out NSAID/DMARD; consider low‑dose glucocorticoid with bone‑protective measures or alternative steroid‑sparing agent.  
- **No:** Rule in NSAID/DMARD as preferred option.  
**Decision:** Choose pathway based on contraindication status.

## STEP 3 — Classify or Stratify
Stratify by disease severity and prognostic features: mild/moderate disease without poor prognostic factors → start NSAID; moderate‑to‑severe disease, high disease activity, or presence of erosions → start conventional DMARD (e.g., methotrexate).  
**Decision:** Select NSAID for mild/moderate cases; select DMARD for more active or high‑risk disease.

## STEP 4 — Decide
Prescribe the chosen NSAID (e.g., ibuprofen 600 mg q6h PRN, naproxen 500 mg BID) or DMARD (e.g., methotrexate 15 mg weekly with folic acid), schedule follow‑up in 4–6 weeks to assess pain, inflammation, weight change, and adverse effects, and educate patient on weight monitoring and lifestyle measures.  
**Action:** Initiate therapy and arrange reassessment.

## Clinical Guardrails / Mimics / Pitfalls
Avoid long‑term glucocorticoids as first line solely for weight concerns; monitor for GI bleeding, renal impairment, and hypertension with NSAIDs; obtain LFTs and CBC before and during methotrexate; do not stop glucocorticoids abruptly if patient already on them — taper while introducing steroid‑sparing agent; consider cardioprotective NSAID (e.g., celecoxib ) in high‑dose naproxen) in patients with cardiovascular risk.

## Clinical Clinical Example
A 58‑year‑old woman with rheumatoid arthritis, BMI 32, mild joint pain, normal renal and hepatic function, no ulcer history, asks which anti‑inflammatory will limit weight gain. No NSAID contraindication → prescribe ibuprofen 600 mg q6h PRN, add methotrexate 15 mg weekly if symptoms persist at 4‑week visit, counsel on weight tracking and diet/exercise.

**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415